Harnessing the benefits of PPARβ/δ agonists

Louise Mackenzie, L.A. Lione

Research output: Contribution to journalArticle

Abstract

Lipid mediators have complex effects on the cell; one of the key transcriptional factors that moderate prolifera- 20tion and inflammatory effects is PPARβ/δ. Following highly successful clinical trials using the PPARβ/δ agonists 21GW501516 for treatment of diabetes, GSK announced that any further research would be discontinued due to 22preclinical trials in rodentswhich linked this drug towide spread tumour development. In this reviewwe outline 23the dualmolecular functions of PPARβ/δ and connect these to the diverse results fromin vitro studies, and draw 24parallelswith the outcomes of animal and human studies. The PPARβ/δ agonists have a great potential in terms of 25therapy, andwe hope to provide some insight into the reasonswhy such contrasting results have been published. 26The discussion presented here is important to the future development of PPARβ/δ agonists for the clinic, and for a 27fuller understanding for their complex regulatory roles in the cell.
Original languageEnglish
Pages (from-to)963-967
Number of pages5
JournalLife Sciences
Volume93
Issue number25-26
DOIs
Publication statusPublished - 18 Dec 2013

Fingerprint

Peroxisome Proliferator-Activated Receptors
Mediator Complex
Clinical Trials
Lipids
Research
Pharmaceutical Preparations
Neoplasms

Cite this

Mackenzie, Louise ; Lione, L.A. / Harnessing the benefits of PPARβ/δ agonists. In: Life Sciences. 2013 ; Vol. 93, No. 25-26. pp. 963-967.
@article{1d27db2d2f494321b41f3a06a7b5b8cb,
title = "Harnessing the benefits of PPARβ/δ agonists",
abstract = "Lipid mediators have complex effects on the cell; one of the key transcriptional factors that moderate prolifera- 20tion and inflammatory effects is PPARβ/δ. Following highly successful clinical trials using the PPARβ/δ agonists 21GW501516 for treatment of diabetes, GSK announced that any further research would be discontinued due to 22preclinical trials in rodentswhich linked this drug towide spread tumour development. In this reviewwe outline 23the dualmolecular functions of PPARβ/δ and connect these to the diverse results fromin vitro studies, and draw 24parallelswith the outcomes of animal and human studies. The PPARβ/δ agonists have a great potential in terms of 25therapy, andwe hope to provide some insight into the reasonswhy such contrasting results have been published. 26The discussion presented here is important to the future development of PPARβ/δ agonists for the clinic, and for a 27fuller understanding for their complex regulatory roles in the cell.",
author = "Louise Mackenzie and L.A. Lione",
year = "2013",
month = "12",
day = "18",
doi = "10.1016/j.lfs.2013.10.022",
language = "English",
volume = "93",
pages = "963--967",
journal = "Life Sciences",
issn = "0024-3205",
number = "25-26",

}

Harnessing the benefits of PPARβ/δ agonists. / Mackenzie, Louise; Lione, L.A.

In: Life Sciences, Vol. 93, No. 25-26, 18.12.2013, p. 963-967.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Harnessing the benefits of PPARβ/δ agonists

AU - Mackenzie, Louise

AU - Lione, L.A.

PY - 2013/12/18

Y1 - 2013/12/18

N2 - Lipid mediators have complex effects on the cell; one of the key transcriptional factors that moderate prolifera- 20tion and inflammatory effects is PPARβ/δ. Following highly successful clinical trials using the PPARβ/δ agonists 21GW501516 for treatment of diabetes, GSK announced that any further research would be discontinued due to 22preclinical trials in rodentswhich linked this drug towide spread tumour development. In this reviewwe outline 23the dualmolecular functions of PPARβ/δ and connect these to the diverse results fromin vitro studies, and draw 24parallelswith the outcomes of animal and human studies. The PPARβ/δ agonists have a great potential in terms of 25therapy, andwe hope to provide some insight into the reasonswhy such contrasting results have been published. 26The discussion presented here is important to the future development of PPARβ/δ agonists for the clinic, and for a 27fuller understanding for their complex regulatory roles in the cell.

AB - Lipid mediators have complex effects on the cell; one of the key transcriptional factors that moderate prolifera- 20tion and inflammatory effects is PPARβ/δ. Following highly successful clinical trials using the PPARβ/δ agonists 21GW501516 for treatment of diabetes, GSK announced that any further research would be discontinued due to 22preclinical trials in rodentswhich linked this drug towide spread tumour development. In this reviewwe outline 23the dualmolecular functions of PPARβ/δ and connect these to the diverse results fromin vitro studies, and draw 24parallelswith the outcomes of animal and human studies. The PPARβ/δ agonists have a great potential in terms of 25therapy, andwe hope to provide some insight into the reasonswhy such contrasting results have been published. 26The discussion presented here is important to the future development of PPARβ/δ agonists for the clinic, and for a 27fuller understanding for their complex regulatory roles in the cell.

U2 - 10.1016/j.lfs.2013.10.022

DO - 10.1016/j.lfs.2013.10.022

M3 - Article

VL - 93

SP - 963

EP - 967

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 25-26

ER -